Paul Ridker, ACC 2022: Secondary analysis of the CANTOS trial of the inflammatory hypothesis of atherothrombosis and chronic kidney disease
The CANTOS trial assessed the differential impact of residual inflammatory risk and residual cholesterol risk among atherosclerosis patients with and without chronic kidney disease. touchCARDIO spoke to Prof Paul Ridker (Harvard University, Boston, MA, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘Secondary Analysis of the CANTOS Trial: Differential Impact of Residual Inflammatory Risk and Residual Cholesterol Risk Among Atherosclerosis Patients With and Without Chronic Kidney Disease’.
ClinicalTrials.gov Identifier: NCT01327846
Questions
- Â Â Â What did the CANTOS study teach us about the clinical utility of inflammation inhibition in cardiovascular risk reduction? 00:16-01:00
- Â Â Â What was the rationale for the current analysis of the CANTOS data? 01:00-02:02
- Â Â Â What were the findings of this analysis? 02:02-03:18
- Â Â Â What are the clinical implications of these findings? 03:18-05:25
- Â Â Â What questions remain unanswered and what future studies are planned? 05:25-06:03
Speaker Disclosure: Paul Ridker is a consultant for Novo Nordisk and Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
